|
1
|
Clarke M: Meta-analyses of adjuvant
therapies for women with early breast cancer: the Early Breast
Cancer Trialists' Collaborative Group overview. Ann Oncol. 17(Suppl
10): x59–x62. 2006. View Article : Google Scholar
|
|
2
|
Fisher B, Costantino JP, Wickerham DL,
Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N,
Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and Wolmark N:
Tamoxifen for prevention of breast cancer: report of the National
Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer
Inst. 90:1371–1388. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katzenellenbogen BS, Fang H, Ince BA,
Pakdel F, Reese JC, Wooge CH and Wrenn CK: William L. McGuire
Memorial Symposium. Estrogen receptors: ligand discrimination and
antiestrogen action. Breast Cancer Res Treat. 27:17–26. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katzenellenbogen BS, Montano MM, Le Goff
P, Schodin DJ, Kraus WL, Bhardwaj B and Fujimoto N: Antiestrogens:
mechanisms and actions in target cells. J Steroid Biochem Mol Biol.
53:387–393. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Charlier C, Chariot A, Antoine N, Merville
MP, Gielen J and Castronovo V: Tamoxifen and its active metabolite
inhibit growth of estrogen receptor-negative MDA-MB-435 cells.
Biochem Pharmacol. 49:351–358. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amin S, Kumar A, Nilchi L, Wright K and
Kozlowski M: Breast cancer cells proliferation is regulated by
tyrosine phosphatase SHP1 through c-jun N-terminal kinase and
cooperative induction of RFX-1 and AP-4 transcription factors. Mol
Cancer Res. 9:1112–1125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mamay CL, Mingo-Sion AM, Wolf DM, Molina
MD and Van Den Berg CL: An inhibitory function for JNK in the
regulation of IGF-I signaling in breast cancer. Oncogene.
22:602–614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montano MM and Katzenellenbogen BS: The
quinone reductase gene: a unique estrogen receptor-regulated gene
that is activated by antiestrogens. Proc Natl Acad Sci USA.
94:2581–2586. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Umekita Y, Ohi Y, Sagara Y and Yoshida H:
Overexpression of cyclinD1 predicts for poor prognosis in estrogen
receptor-negative breast cancer patients. Int J Cancer. 98:415–418.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Altucci L, Addeo R, Cicatiello L, Dauvois
S, Parker MG, Truss M, Beato M, Sica V, Bresciani F and Weisz A:
17beta-Estradiol induces cyclin D1 gene transcription,
p36D1-p34cdk4 complex activation and p105Rb phosphorylation during
mitogenic stimulation of G(1)-arrested human breast cancer cells.
Oncogene. 12:2315–2324. 1996.
|
|
11
|
Fu XD, Cui YH, Lin GP and Wang TH:
Non-genomic effects of 17beta-estradiol in activation of the
ERK1/ERK2 pathway induces cell proliferation through upregulation
of cyclin D1 expression in bovine artery endothelial cells. Gynecol
Endocrinol. 23:131–137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urtreger AJ, Kazanietz MG and Bal de Kier
Joffe ED: Contribution of individual PKC isoforms to breast cancer
progression. IUBMB Life. 64:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Orchel A, Dzierzewicz Z, Parfiniewicz B,
Weglarz L and Wilczok T: Butyrate-induced differentiation of colon
cancer cells is PKC and JNK dependent. Dig Dis Sci. 50:490–498.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu DS, Krebs CE and Liu SJ: Proliferation
of human breast cancer cells and anti-cancer action of doxorubicin
and vinblastine are independent of PKC-alpha. J Cell Biochem.
101:517–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Wang N, Fang J, Huang J, Tian F, Li
C and Xie F: Role of PKC-ERK signaling in tamoxifen-induced
apoptosis and tamoxifen resistance in human breast cancer cells.
Oncol Rep. 27:1879–1886. 2012.PubMed/NCBI
|
|
16
|
Stabel S and Parker PJ: Protein kinase C.
Pharmacol Ther. 51:71–95. 1991. View Article : Google Scholar
|
|
17
|
Newton AC: Protein kinase C: structure,
function and regulation. J Biol Chem. 270:28495–28498. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Newton AC: Regulation of protein kinase C.
Curr Opin Cell Biol. 9:161–167. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fisher B, Dignam J, Bryant J, DeCillis A,
Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman
DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H,
et al: Five versus more than five years of tamoxifen therapy for
breast cancer patients with negative lymph nodes and estrogen
receptor-positive tumors. J Natl Cancer Inst. 88:1529–1542.
1996.
|
|
20
|
Berstein LM, Zheng H, Yue W, Wang JP,
Lykkesfeldt AE, Naftolin F, Harada H, Shanabrough M and Santen RJ:
New approaches to the understanding of tamoxifen action and
resistance. Endocr Relat Cancer. 10:267–277. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Santen RJ: Long-term tamoxifen therapy:
can an antagonist become an agonist? J Clin Endocrinol Metab.
81:2027–2029. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shanmugam M, Krett NL, Maizels ET, Cutler
RE Jr, Peters CA, Smith LM, O'Brien ML, Park-Sarge OK, Rosen ST and
Hunzicker-Dunn M: Regulation of protein kinase C delta by estrogen
in the MCF-7 human breast cancer cell line. Mol Cell Endocrinol.
148:109–118. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Keshamouni VG, Mattingly RR and Reddy KB:
Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast
cancer cells. A role for HER2 AND PKC-delta. J Biol Chem.
277:22558–22565. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka Y, Gavrielides MV, Mitsuuchi Y,
Fujii T and Kazanietz MG: Protein kinase C promotes apoptosis in
LNCaP prostate cancer cells through activation of p38 MAPK and
inhibition of the Akt survival pathway. J Biol Chem.
278:33753–33762. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jarzabek K, Laudanski P, Dzieciol J,
Dabrowska M and Wolczynski S: Protein kinase C involvement in
proliferation and survival of breast cancer cells. Folia Histochem
Cytobiol. 40:193–194. 2002.PubMed/NCBI
|
|
26
|
Liu JF, Crepin M, Liu JM, Barritault D and
Ledoux D: FGF-2 and TPA induce matrix metalloproteinase-9 secretion
in MCF-7 cells through PKC activation of the Ras/ERK pathway.
Biochem Biophys Res Commun. 293:1174–1182. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grossoni VC, Falbo KB, Kazanietz MG, de
Kier Joffe ED and Urtreger AJ: Protein kinase C delta enhances
proliferation and survival of murine mammary cells. Mol Carcinog.
46:381–390. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kiley SC, Clark KJ, Duddy SK, Welch DR and
Jaken S: Increased protein kinase C delta in mammary tumor cells:
relationship to transformation and metastatic progression.
Oncogene. 18:6748–6757. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lonne GK, Masoumi KC, Lennartsson J and
Larsson C: Protein kinase Cdelta supports survival of MDA-MB-231
breast cancer cells by suppressing the ERK1/2 pathway. J Biol Chem.
284:33456–33465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vucenik I, Ramakrishna G, Tantivejkul K,
Anderson LM and Ramljak D: Inositol hexaphosphate (IP6) blocks
proliferation of human breast cancer cells through a
PKCdelta-dependent increase in p27Kip1 and decrease in
retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res
Treat. 91:35–45. 2005. View Article : Google Scholar
|
|
31
|
Assender JW, Gee JM, Lewis I, Ellis IO,
Robertson JF and Nicholson RI: Protein kinase C isoform expression
as a predictor of disease outcome on endocrine therapy in breast
cancer. J Clin Pathol. 60:1216–1221. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nabha SM, Glaros S, Hong M, Lykkesfeldt
AE, Schiff R, Osborne K and Reddy KB: Upregulation of PKC-delta
contributes to antiestrogen resistance in mammary tumor cells.
Oncogene. 24:3166–3176. 2005. View Article : Google Scholar : PubMed/NCBI
|
